Drug intelligence / Profile preview

SclerFIX

Development stage: Phase 1
Lead developer: TBF Génie Tissulaire
Administration: Ophthalmic

Overview

SclerFIX is a biological allograft developed by TBF Genie Tissulaire for the repair and reinforcement of the sclera. It is composed of devitalized, dehydrated, and viro-inactivated allogeneic human tissue derived from the sterile umbilical cord wall (amniotic membrane). Developed as a substitute for traditional scleral grafts, SclerFIX is used to treat scleral thinning, fill defects after the excision of conjunctival lesions or tumors, and assist in reconstruction after enucleation. The product is provided as a flat, freeze-dried tissue that can be stored at room temperature and is currently being evaluated in Phase II clinical trials for reinforcing the sclera following ocular surface tumor removal.

Brand names: SclerFIX
Other names: Umbilical cord lining membrane allograftSclerFIX graft

Beyond the preview

Go deeper on SclerFIX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SclerFIX.

Explore the full profile